Alivus Life Sciences Ltd (ALIV)

Currency in INR
935.00
+46.80(+5.27%)
Closed·
ALIV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
880.65937.00
52 wk Range
819.001,251.00
Key Statistics
Bid/Ask
932.70 / 935.00
Prev. Close
888.2
Open
886
Day's Range
880.65-937
52 wk Range
819-1,251
Volume
152.17K
Average Volume (3m)
93.13K
1-Year Change
-18.9248%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALIV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1,229.25
Upside
+31.47%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility

Alivus Life Sciences Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Alivus Life Sciences Ltd Company Profile

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.

Employees
2203
Market
India

Compare ALIV to Peers and Sector

Metrics to compare
ALIV
Peers
Sector
Relationship
P/E Ratio
20.1x27.7x−0.6x
PEG Ratio
0.871.090.00
Price/Book
3.6x3.6x2.6x
Price / LTM Sales
4.3x4.3x3.4x
Upside (Analyst Target)
34.0%29.7%42.5%
Fair Value Upside
Unlock22.2%5.0%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1,229.25
(+31.47% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 44.23%
Dividend Yield
0.56%
Industry Median 0.75%
Annualised payout
5.00
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Jan 22, 2026
EPS / Forecast
12.75 / --
Revenue / Forecast
6.73B / 6.74B
EPS Revisions
Last 90 days

ALIV Income Statement

FAQ

What Is the Alivus Life Sciences (ALIV) Stock Price Today?

The Alivus Life Sciences stock price today is 935,00

What Stock Exchange Does Alivus Life Sciences Trade On?

Alivus Life Sciences is listed and trades on the India National Stock Exchange stock exchange.

What Is the Stock Symbol for Alivus Life Sciences?

The stock symbol for Alivus Life Sciences is "ALIV."

Does Alivus Life Sciences Pay Dividends? What’s The Current Dividend Yield?

The Alivus Life Sciences dividend yield is 0.56%.

What Is the Alivus Life Sciences Market Cap?

As of today, Alivus Life Sciences market cap is 109.01B.

What Is Alivus Life Sciences's Earnings Per Share (TTM)?

The Alivus Life Sciences EPS (TTM) is 44.23.

When Is the Next Alivus Life Sciences Earnings Date?

Alivus Life Sciences will release its next earnings report on 22 Apr 2026.

From a Technical Analysis Perspective, Is ALIV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Alivus Life Sciences Stock Split?

Alivus Life Sciences has split 0 times.

How Many Employees Does Alivus Life Sciences Have?

Alivus Life Sciences has 2203 employees.

What is the current trading status of Alivus Life Sciences (ALIV)?

As of 28 Jan 2026, Alivus Life Sciences (ALIV) is trading at a price of 935,00, with a previous close of 888,20. The stock has fluctuated within a day range of 880,65 to 937,00, while its 52-week range spans from 819,00 to 1 251,00.

What Is Alivus Life Sciences (ALIV) Price Target According to Analysts?

The average 12-month price target for Alivus Life Sciences is INR1 229,25, with a high estimate of INR1382 and a low estimate of INR1155. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +31,47% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.